417 POSTER Maintenance hormone therapy with letrozole after first-line chemotherapy in postmenopausal patients with hormone receptor-positive metastatic breast cancer
European Journal of Cancer Supplements. 2005;3(2):117 
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial
The Breast. 2012;21(1):27-33
Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting
Breast Cancer Research and Treatment. 2017;163(3):635-635
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea
Cancer Research and Treatment. 2017;49(2):454-463
5048 A Q-TWiST analysis of lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive (HR+) metastatic breast cancer (MBC)
European Journal of Cancer Supplements. 2009;7(2):275
PR86 RETROSPECTIVE STUDY OF EVEROLIMUS WITH FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER PRETREATED WITH AROMATASE INHIBITORS(AI'S) AND SELECTIVE ESTROGEN MODIFIERS
The Breast. 2015;24:S51
Letrozole in First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women Is Superior to Tamoxifen
Clinical Breast Cancer. 2001;1(4):272-273
A phase II parallel group study with letrozole plus goserelin in premenopausal, and letrozole in postmenopausal metastatic breast cancer patients as first line hormone therapy
European Journal of Cancer Supplements. 2008;6(7):176
0161 Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Update of the BIG 1-98 primary core analysis
The Breast. 2009;18:S60
S4 Letrozole vs. Tamoxifen as adjuvant endocrine therapy for postmenopausal women in receptor-positive breast cancer. BIG 1-98: A prospective randomized double-blind phase III study
The Breast. 2005;14:S3